Damora Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
DMRA$24.15+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
(in thousands, except share amounts)
| Mezzanine Equity · Stockholders’ Equity | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Series B Non-Voting Convertible Preferred Stock · Series C Non-Voting Convertible Preferred Stock · Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | |||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Income (Loss) · Equity | |||||||||||||
| Balance at December 31, 2023 | — | — | — | — | — | — | 1,084,509 | — | 288,036 | (256,085) | 380 | 32,331 | |
| Stock-based compensation expense | — | — | — | — | — | — | — | — | 3,239 | — | — | 3,239 | |
| Issuance of common stock in connection with vesting of restricted stock units | — | — | — | — | — | — | 6,828 | — | 93 | — | — | 93 | |
| Issuance of preferred and common stock in connection with an Asset Purchase Agreement | 161 | 1,360 | — | — | — | — | 62,594 | — | 530 | — | — | 1,890 | |
| Round-up shares from the 1-for-25 reverse split effective August 29, 2024 | — | — | — | — | — | — | 163,058 | — | — | — | — | — | |
| Other comprehensive loss, net | — | — | — | — | — | — | — | — | — | — | (283) | (283) | |
| Net loss | — | — | — | — | — | — | — | — | — | (21,439) | — | (21,439) | |
| Balance at December 31, 2024 | 161 | $1,360 | — | $— | — | $— | 1,316,989 | $— | $291,898 | $(277,524) | $97 | $15,831 | |
| Stock-based compensation expense | 998 | 998 | |||||||||||
| Issuance of Series B and C non-voting convertible preferred and common stock in connection with the asset acquisition of Damora Therapeutics, Inc. | — | — | 16,366 | 117,621 | 4,241 | 30,480 | 265,309 | — | 4,576 | — | — | 152,677 | |
| Issuance of Series C non-voting convertible preferred stock in connection with private placement, net of issuance costs | — | — | — | — | 39,641 | 266,811 | — | — | — | — | — | 266,811 | |
| Issuance of Paramora Warrant | — | — | — | — | — | — | — | — | 13,125 | — | — | 13,125 | |
| Issuance of preferred and common stock in connection with an Asset Purchase Agreement | (2) | (19) | — | — | — | — | 2,201 | — | 19 | — | — | — | |
| Issuance of common stock in connection with vesting of restricted stock units | — | — | — | — | — | — | 8,022 | — | 39 | — | — | 39 | |
| Exercise of stock options | — | — | — | — | — | — | 4,800 | — | 33 | — | — | 33 | |
| Other comprehensive loss, net | — | — | — | — | — | — | — | — | — | — | 705 | 705 | |
| Net loss | — | — | — | — | — | — | — | — | — | (209,839) | — | (209,839) | |
| Balance at December 31, 2025 | 159 | $1,341 | 16,366 | $117,621 | 43,882 | $297,291 | 1,597,321 | $— | $310,688 | $(487,363) | $802 | $240,380 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.